Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression
Marco Krasselt · 2026
Read Recombinant zoster vaccine in patients with inflammatory rheumatic diseases: efficacy, long-term protection and safety under immunosuppression by Marco Krasselt (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13185007.txt.
Description
Marco Krasselt reviews the shingles vaccine for people whose immune systems are damped by disease and drugs, in this solo review from twenty twenty-six. People with inflammatory rheumatic diseases catch shingles far more often than others, helped along by immune-suppressing drugs. The vaccine in question is a recombinant shot, not a live virus, and it guards healthy older adults for at least ten years.
Newer studies in these patients show strong protection, with one real-world cohort seeing relapses of shingles fall by about ninety-five percent after vaccination. The worry is flares of the underlying disease. One safety database flagged flares in a small share of patients, while trials found no clear rise against placebo. Major guidelines now back two doses for adults at risk, even on strong immune drugs. Krasselt's advice is to vaccinate, warn patients about short-term flares, and watch them briefly afterward.
Catalog record
| CREATOR | Marco Krasselt |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |